Tarceva for Kidney cancer
Papillary Renal Cell Carcinoma makes up approximately 10% to 20% of kidney cancers. These tumors are thought of as being relatively resistant to immunotherapy with some of the newer drugs, of the groups TKI and mTOR inhibitors. Examples of such drugs are Sutent and Torisel. For this reason, Tarceva(erlotinib) has been studiedespecially in the papillary renal cell cancer. There is a reported response rate in low teens and the disease control rate
Read more